BioCentury
ARTICLE | Clinical News

Oritavancin: Phase III data

December 24, 2012 8:00 AM UTC

In patients with microbiologically-confirmed methicillin-resistant Staphylococcus aureus (MRSA) infection (n=204), 80.8% of patients receiving oritavancin achieved an early clinical response vs. 80% f...